Published in Adv Drug Deliv Rev on April 17, 2009
Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol (2012) 3.48
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Toxicity of nanomaterials. Chem Soc Rev (2011) 2.07
Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol (2011) 1.90
Nanoparticles and the immune system. Endocrinology (2009) 1.79
PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett (2012) 1.77
An index for characterization of nanomaterials in biological systems. Nat Nanotechnol (2010) 1.69
Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano (2010) 1.46
Nano meets biology: structure and function at the nanoparticle interface. Langmuir (2011) 1.43
Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials (2011) 1.20
Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology (2011) 1.19
The role of surface functionality in determining nanoparticle cytotoxicity. Acc Chem Res (2013) 1.17
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci (2013) 1.16
Inorganic nanoparticles in cancer therapy. Pharm Res (2010) 1.11
Validity range of centrifuges for the regulation of nanomaterials: from classification to as-tested coronas. J Nanopart Res (2012) 1.10
The adsorption of biomolecules to multi-walled carbon nanotubes is influenced by both pulmonary surfactant lipids and surface chemistry. J Nanobiotechnology (2010) 1.08
Beauty is skin deep: a surface monolayer perspective on nanoparticle interactions with cells and bio-macromolecules. Small (2011) 1.08
Fabrication of corona-free nanoparticles with tunable hydrophobicity. ACS Nano (2014) 1.07
Chemical basis of interactions between engineered nanoparticles and biological systems. Chem Rev (2014) 1.07
Nanocarriers for vascular delivery of antioxidants. Nanomedicine (Lond) (2011) 1.06
Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther (2011) 1.06
Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev (2013) 1.05
Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat Nanotechnol (2016) 1.01
ICP-MS analysis of lanthanide-doped nanoparticles as a non-radiative, multiplex approach to quantify biodistribution and blood clearance. Biomaterials (2011) 1.00
Altered characteristics of silica nanoparticles in bovine and human serum: the importance of nanomaterial characterization prior to its toxicological evaluation. Part Fibre Toxicol (2013) 0.98
Real time monitoring of biomaterial-mediated inflammatory responses via macrophage-targeting NIR nanoprobes. Biomaterials (2011) 0.98
A general mechanism for intracellular toxicity of metal-containing nanoparticles. Nanoscale (2014) 0.98
Zwitteration: coating surfaces with zwitterionic functionality to reduce nonspecific adsorption. Langmuir (2014) 0.96
Biomolecular corona on nanoparticles: a survey of recent literature and its implications in targeted drug delivery. Front Chem (2014) 0.95
Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int J Nanomedicine (2013) 0.95
Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One (2012) 0.95
The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front Immunol (2013) 0.94
Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano (2014) 0.94
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev (2015) 0.92
Physicochemical properties of nanomaterials: implication in associated toxic manifestations. Biomed Res Int (2014) 0.92
Detection and characterization of subvisible aggregates of monoclonal IgG in serum. Pharm Res (2012) 0.92
Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomedicine (2010) 0.92
Bions: a family of biomimetic mineralo-organic complexes derived from biological fluids. PLoS One (2013) 0.91
Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles. Sci Rep (2013) 0.91
Nanodetoxification: emerging role of nanomaterials in drug intoxication treatment. Nanomedicine (Lond) (2011) 0.91
Novel formulations for antimicrobial peptides. Int J Mol Sci (2014) 0.91
Functionalized Gold Nanoparticles and Their Biomedical Applications. Nanomaterials (Basel) (2011) 0.90
Accounting for biological aggregation in heating and imaging of magnetic nanoparticles. Technology (Singap World Sci) (2014) 0.90
Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine (Lond) (2013) 0.90
Probing of the assembly structure and dynamics within nanoparticles during interaction with blood proteins. ACS Nano (2012) 0.90
Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efficient tumor imaging. ACS Nano (2013) 0.89
Barriers to drug delivery in solid tumors. Tissue Barriers (2014) 0.89
The interplay of monolayer structure and serum protein interactions on the cellular uptake of gold nanoparticles. Small (2012) 0.89
Effects of 15d-PGJ₂-loaded poly(D,L-lactide-co-glycolide) nanocapsules on inflammation. Br J Pharmacol (2011) 0.88
Protein bio-corona: critical issue in immune nanotoxicology. Arch Toxicol (2016) 0.87
Silica nanoconstruct cellular toleration threshold in vitro. J Control Release (2011) 0.87
Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol (2012) 0.87
The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond) (2015) 0.86
Immune complement activation is attenuated by surface nanotopography. Int J Nanomedicine (2011) 0.86
Drug delivery interfaces in the 21st century: from science fiction ideas to viable technologies. Mol Pharm (2013) 0.86
Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization. Proc Natl Acad Sci U S A (2016) 0.85
Analytical strategies for detecting nanoparticle-protein interactions. Analyst (2010) 0.85
In vivo molecular imaging using nanomaterials: general in vivo characteristics of nano-sized reagents and applications for cancer diagnosis. Mol Membr Biol (2010) 0.85
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
Nanoparticle Uptake: The Phagocyte Problem. Nano Today (2015) 0.84
Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomedicine (2012) 0.84
Nanotechnology and the treatment of HIV infection. Viruses (2012) 0.84
Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism. Biomaterials (2015) 0.83
Exploration of possible binding sites of nanoparticles on protein by cross-linking chemistry coupled with mass spectrometry. Anal Chem (2011) 0.83
Measuring the grafting density of nanoparticles in solution by analytical ultracentrifugation and total organic carbon analysis. Anal Chem (2012) 0.83
The effect of blood protein adsorption on cellular uptake of anatase TiO2 nanoparticles. Int J Nanomedicine (2015) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics (2016) 0.83
The biomechanisms of metal and metal-oxide nanoparticles' interactions with cells. Int J Environ Res Public Health (2015) 0.82
Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int J Nanomedicine (2015) 0.82
Protein corona - from molecular adsorption to physiological complexity. Beilstein J Nanotechnol (2015) 0.82
Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta Biomater (2015) 0.82
Protein-based photothermal theranostics for imaging-guided cancer therapy. Nanoscale (2015) 0.82
Evaluation of silica nanoparticle binding to major human blood proteins. Nanoscale Res Lett (2014) 0.81
Effect of pullulan nanoparticle surface charges on HSA complexation and drug release behavior of HSA-bound nanoparticles. PLoS One (2012) 0.81
Merging worlds of nanomaterials and biological environment: factors governing protein corona formation on nanoparticles and its biological consequences. Nanoscale Res Lett (2015) 0.81
Progress on the diagnosis and evaluation of brain tumors. Cancer Imaging (2013) 0.81
Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles. PLoS One (2014) 0.81
15d-PGJ2 Reduced Microglia Activation and Alleviated Neurological Deficit of Ischemic Reperfusion in Diabetic Rat Model. Biomed Res Int (2015) 0.80
Using the Power of Organic Synthesis for Engineering the Interactions of Nanoparticles with Biological Systems. Nano Today (2016) 0.80
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Control Release (2015) 0.79
A one-step electrospray-based technique for modulating morphology and surface properties of poly(lactide-co-glycolide) microparticles using Pluronics®. Int J Nanomedicine (2012) 0.79
Endocytosis in gene therapy with non-viral vectors. Wien Med Wochenschr (2016) 0.79
Colloidal stability of polymeric nanoparticles in biological fluids. J Nanopart Res (2012) 0.79
Interaction of silicon-based quantum dots with gibel carp liver: oxidative and structural modifications. Nanoscale Res Lett (2013) 0.79
Structural determinants for protein adsorption/non-adsorption to silica surface. PLoS One (2013) 0.79
Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B (2016) 0.79
Spherical nucleic acid nanoparticle conjugates enhance G-quadruplex formation and increase serum protein interactions. Angew Chem Int Ed Engl (2014) 0.78
Cellular Uptake Mechanism of Paclitaxel Nanocrystals Determined by Confocal Imaging and Kinetic Measurement. AAPS J (2015) 0.78
The janus facet of nanomaterials. Biomed Res Int (2015) 0.78
Effect of nano-scale curvature on the intrinsic blood coagulation system. Nanoscale (2014) 0.78
Manganese ferrite-based nanoparticles induce ex vivo, but not in vivo, cardiovascular effects. Int J Nanomedicine (2014) 0.78
Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab (2013) 0.78
PEG-b-AGE Polymer Coated Magnetic Nanoparticle Probes with Facile Functionalization and Anti-fouling Properties for Reducing Non-specific Uptake and Improving Biomarker Targeting. J Mater Chem B Mater Biol Med (2015) 0.78
Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy. Sci Rep (2016) 0.78
Stimulating antitumor immunity with nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.78
Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers. J Biol Eng (2012) 0.78
The fate of calcium carbonate nanoparticles administered by oral route: absorption and their interaction with biological matrices. Int J Nanomedicine (2015) 0.78
Engineered metal based nanoparticles and innate immunity. Clin Mol Allergy (2015) 0.78
Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett (2006) 10.12
Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev (2001) 10.02
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm (2005) 7.53
Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A (2007) 7.50
Biodegradable long-circulating polymeric nanospheres. Science (1994) 7.46
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res (2006) 4.99
Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res (1984) 4.12
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res (2003) 3.89
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials (2008) 3.68
Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv (2004) 3.65
Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl (2007) 3.41
Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol (2001) 3.38
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces (2000) 3.33
Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci U S A (2007) 3.23
Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev (2001) 3.01
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Role of the alveolar macrophage in lung injury: studies with ultrafine particles. Environ Health Perspect (1992) 2.76
The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci (2007) 2.22
Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans (2007) 2.19
Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials (2007) 2.19
Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev (2008) 2.06
The role of complement in inflammation and phagocytosis. Immunol Today (1991) 2.04
The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev (1995) 2.03
Nanotechnology for the biologist. J Leukoc Biol (2005) 2.03
The pulmonary toxicology of ultrafine particles. J Aerosol Med (2002) 2.02
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target (2002) 2.02
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (2008) 1.99
Inhalation of poorly soluble particles. II. Influence Of particle surface area on inflammation and clearance. Inhal Toxicol (2000) 1.99
Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. Langmuir (2004) 1.86
Complement activation and protein adsorption by carbon nanotubes. Mol Immunol (2005) 1.81
Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol (2003) 1.81
Protein adsorption onto silica nanoparticles: conformational changes depend on the particles' curvature and the protein stability. Langmuir (2004) 1.80
Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci (2007) 1.77
Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm (2000) 1.73
In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci (2005) 1.72
Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J Biomed Mater Res A (2003) 1.69
Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res (1995) 1.68
Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem (1992) 1.63
Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm (2002) 1.55
Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer (2004) 1.54
Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm (1998) 1.54
Structure and function of enzymes adsorbed onto single-walled carbon nanotubes. Langmuir (2004) 1.52
Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res (1998) 1.51
Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res (1999) 1.48
Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev (1984) 1.47
Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release (1999) 1.47
Surface tailoring for controlled protein adsorption: effect of topography at the nanometer scale and chemistry. J Am Chem Soc (2006) 1.47
Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). Langmuir (2006) 1.37
Influence of fluorescent labelling of polystyrene particles on phagocytic uptake, surface hydrophobicity, and plasma protein adsorption. Pharm Res (1997) 1.37
Drug transport to brain with targeted nanoparticles. NeuroRx (2005) 1.37
Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target (2005) 1.36
Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci (2003) 1.35
Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol (2001) 1.32
Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther (2006) 1.32
Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol (2002) 1.28
Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis (1993) 1.27
Probing the interactions of proteins and nanoparticles. Proc Natl Acad Sci U S A (2007) 1.26
Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood (1980) 1.25
Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. Adv Drug Deliv Rev (1998) 1.22
Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneimittelforschung (1977) 1.22
140 mouse brain proteins identified by Ca2+-calmodulin affinity chromatography and tandem mass spectrometry. J Proteome Res (2006) 1.21
Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Crit Rev Ther Drug Carrier Syst (1994) 1.21
Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm (2007) 1.20
Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release (2006) 1.18
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol (2000) 1.16
Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials (1999) 1.16
Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm (2001) 1.15
Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials (2005) 1.14
Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials (2006) 1.12
Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett (2006) 1.10
Kinetics of blood component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of complement C3 component involvement. J Biomed Mater Res (1997) 1.09
Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta (1993) 1.08
Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul (1998) 1.07
Plasma protein adsorption patterns on liposomes: establishment of analytical procedure. Electrophoresis (1996) 1.07
Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carrier Syst (2001) 1.06
Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst (1992) 1.06
Probing protein adsorption onto mercaptoundecanoic acid stabilized gold nanoparticles and surfaces by quartz crystal microbalance and zeta-potential measurements. Langmuir (2007) 1.05
Nanoparticles as catalysts for protein fibrillation. Proc Natl Acad Sci U S A (2007) 1.00
The effect of serum protein fractions on liposome-cell interactions in cultured cells and the perfused rat liver. Biochim Biophys Acta (1977) 1.00
Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur J Pharm Biopharm (2005) 1.00
Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis (2007) 1.00
Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm (2005) 0.99
Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition. J Control Release (1998) 0.96
Binding between particles and proteins in extracts: implications for microrheology and toxicity. Acta Biomater (2005) 0.95
An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. Life Sci (1995) 0.95
Development of a high throughput equilibrium dialysis method. J Pharm Sci (2001) 0.94
Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. J Control Release (2004) 0.94
Dendrimer interactions with hydrophobic fluorescent probes and human serum albumin. J Fluoresc (2005) 0.93
The protein-nanomaterial interface. Curr Opin Biotechnol (2006) 0.93
Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles. J Biomed Mater Res A (2008) 0.92
Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules (2007) 0.92
Increasing protein stability through control of the nanoscale environment. Langmuir (2006) 0.92
Anomalous thermal denaturing of proteins adsorbed to nanoparticles. Eur Phys J E Soft Matter (2006) 0.91
Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Int J Pharm (2006) 0.91
Directed assembly of carbon nanotubes at liquid-liquid interfaces: nanoscale conveyors for interfacial biocatalysis. J Am Chem Soc (2006) 0.91
The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. Life Sci (1987) 0.89
Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake. Clin Nutr (1992) 0.87
Determination of plasma protein adsorption on magnetic iron oxides: sample preparation. Pharm Res (1997) 0.86
Dendrimer-protein interactions studied by tryptophan room temperature phosphorescence. Biochim Biophys Acta (2006) 0.86
Molecular mechanisms of the adsorption of a model protein (human serum albumin) on poly(methylidene malonate 2.1.2) nanoparticles. Pharm Res (1999) 0.85
Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Nanotechnology safety concerns revisited. Toxicol Sci (2007) 2.41
Human in vivo radiation-induced biomarkers: gene expression changes in radiotherapy patients. Cancer Res (2004) 2.04
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (2008) 1.99
Nanoparticles and the immune system. Endocrinology (2009) 1.79
Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) (2007) 1.62
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb) (2013) 1.30
Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.30
Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat Protoc (2011) 1.27
Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos (2008) 1.24
Induction of autophagy in porcine kidney cells by quantum dots: a common cellular response to nanomaterials? Toxicol Sci (2008) 1.23
Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett (2008) 1.20
Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicol Appl Pharmacol (2010) 1.20
Translational considerations for cancer nanomedicine. J Control Release (2010) 1.12
Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles. Toxicol Sci (2010) 1.11
Development and assessment of a quantitative reverse transcription-PCR assay for simultaneous measurement of four amplicons. Clin Chem (2003) 1.05
Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm (2011) 1.01
Identification and avoidance of potential artifacts and misinterpretations in nanomaterial ecotoxicity measurements. Environ Sci Technol (2014) 0.95
Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) (2010) 0.95
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
Measurement of 15N relaxation in deuterated amide groups in proteins using direct nitrogen detection. J Biomol NMR (2006) 0.92
Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays. Methods Mol Biol (2011) 0.92
Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine (Lond) (2013) 0.90
Activation of the MAP kinase cascade by exogenous calcium-sensing receptor. Mol Cell Endocrinol (2003) 0.89
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond) (2011) 0.89
Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles. ACS Nano (2014) 0.88
Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci (2014) 0.88
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release (2013) 0.87
Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond) (2011) 0.87
Spin-state selection for increased confidence in cross-correlation rates measurements. J Biomol NMR (2005) 0.85
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Drug Deliv (2015) 0.83
Quantitative characterization of quantum dot-labeled lambda phage for Escherichia coli detection. Biotechnol Bioeng (2009) 0.82
Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine (Lond) (2013) 0.82
In vitro analysis of nanoparticle uptake by macrophages using chemiluminescence. Methods Mol Biol (2011) 0.81
Qualitative analysis of total complement activation by nanoparticles. Methods Mol Biol (2011) 0.81
Choice of method for endotoxin detection depends on nanoformulation. Nanomedicine (Lond) (2013) 0.80
Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett (2013) 0.80
Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity. Nanomedicine (Lond) (2013) 0.80
Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm (2013) 0.79
Gold nanoparticle quantitation via fluorescence in solution and cell culture. Methods Mol Biol (2011) 0.79
Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Biol Ther (2015) 0.78
Method for analysis of nanoparticle hemolytic properties in vitro. Methods Mol Biol (2011) 0.77
Method for in vitro analysis of nanoparticle thrombogenic properties. Methods Mol Biol (2011) 0.76
Analysis of fullerene-based nanomaterial in serum matrix by CE. Electrophoresis (2007) 0.75
Application of a Scavenger Receptor A1 Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV. Mol Pharm (2020) 0.75
Analysis of microbial contamination in nanoparticle formulations. Methods Mol Biol (2011) 0.75
A novel cell-based system for the rapid quantitative evaluation of (anti)-inflammatory potential of test substances. J Immunol Methods (2003) 0.75
Quantitative analysis of PEG-functionalized colloidal gold nanoparticles using charged aerosol detection. Anal Bioanal Chem (2015) 0.75
Method for analysis of nanoparticle effects on cellular chemotaxis. Methods Mol Biol (2011) 0.75